Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Abuckatatime who wrote (16739)	3/7/1998 6:13:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Greg, Thanks for the references. I am planning to add a STATs page to Links to Ligand. This weekend is pretty tough, but if you have any more good background article please post them. About 25% of LGND's effort targets STATS with about 75% directed to IRs. Since IR's are more advanced they get most of the press coverage. However, the hematopoetic growth factors, internal Interleukin programs, and leptin signaling should start to generate some press release, so it's time to give the technology a bit more exposure at the Links to Ligand site.